Impact of oestrogens on the progression of liver disease

Liver International

Volumn 23, Issue 1, 2003, Pages 63-69

  Shimizu, Ichiro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Estradiol; Hepatic fibrosis; Hepatic steatosis; Hepatic stellate cell; Hepatitis C virus; Menopause; Oestrogen receptor; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANTIFIBROTIC AGENT; ANTIOXIDANT; AROMATASE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SILIBININ; TRANSCRIPTION FACTOR AP 1; XIAO CHAI HU TANG; REACTIVE OXYGEN METABOLITE;

BREAST CANCER; CELL ACTIVATION; CHRONIC HEPATITIS; CLINICAL FEATURE; DISEASE EXACERBATION; DISEASE MODEL; DISEASE PREDISPOSITION; DRUG EFFICACY; ENDOMETRIAL DISEASE; EXTRACELLULAR MATRIX; FATTY LIVER; HEPATITIS C; HUMAN; INFLAMMATION; LIPID PEROXIDATION; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CULTURE; LIVER DISEASE; LIVER FIBROSIS; OXIDATIVE STRESS; POSTMENOPAUSE; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVIEW; SEX DIFFERENCE; STELLATE CELL; DISEASE COURSE; FEMALE; FIBROSIS; IRON OVERLOAD; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MENOPAUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; ESTROGENS; FEMALE; FIBROSIS; HEPATITIS C, CHRONIC; HUMANS; IRON OVERLOAD; LIVER; LIVER NEOPLASMS; MALE; MENOPAUSE; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RECEPTORS, ESTROGEN; SEX FACTORS;

EID: 0038207707     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0676.2003.00811.x     Document Type: Review

References (84)

1. McMahon B J, Alberts S R, Wainwright R B, et al. Hepatitis B-related sequelae: prospective study in 1400 hepatitis B surface antigen-positive Alaska native carriers. Arch Intern Med 1990; 150: 1051-4.
2. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001; 34: 730-9.
3. Takano S, Yokosuka O, Imazeki F, et al. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 1995; 21: 650-5.
4. Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B-and C-viral infection in Japan. Hepatology 1995; 22: 1027-33.
5. Houglum K, Filip M, Witztum J L, et al. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload. J Clin Invest 1990; 86: 1991-8.
6. Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 2000; 21: 49-98.
7. Yoshino K, Komura S, Watanabe I, et al. Effect of estrogens on serum and liver lipid peroxide levels in mice. J Clin Biochem Nutr 1987; 3: 233-9.
8. Lacort M, Leal A M, Liza M, et al. Protective effect of estrogens and catecholestrogens against peroxidative membrane damage in vitro. Lipids 1995; 30: 141-6.
9. Omoya T, Shimizu I, Zhou Y, et al. Effects of idoxifene and estradiol on NF-κB activation in cultured rat hepatocytes undergoing oxidative stress. Liver 2001; 21: 183-91.
10. Cui X, Shmizu I, Lu G, et al. Idoxifene and estradiol enhance antiapoptotic activity through the estrogen receptor beta in cultured rat hepatocytes. Dig Dis Sci, 2003. (in press)
11. Carson-Jurica M A, Schrader W T, O'Malley B W. Steroid receptor family: structure and functions. Endocr Rev 1990; 11: 201-20.
12. Kuiper G G, Enmark E, Pelto-Huikko M, et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 1996; 93: 5925-30.
13. Paech K, Webb P, Kuiper G G, et al. Differential ligand activation of estrogen receptors ER α and ER β at AP1 sites. Science 1997; 277: 1508-10.
14. Zhou Y, Shimizu I, Lu G, et al. Hepatic stellate cells contain the functional estrogen receptor β but not the estrogen receptor α in male and female rats. Biochem Biophys Res Commun 2001; 286: 1059-65.
15. Hockenbery D M, Oltvai Z N, Yin X M, et al. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241-51.
16. Kane D J, Sarafian T A, Anton R, et al. Bcl-2 inhibition of neural death: decreased generation of reactive oxygen species. Science 1993; 262: 1274-7.
17. Ray P, Ghosh S K, Zhang D H, et al. Repression of interleukin-6 gene expression by 17β-estradiol: inhibition of the DNA-binding activity of the transcription factors NF-IL6 and NF-κB by the estrogen receptor. FEBS Lett 1997; 409: 79-85.
18. Sun W H, Keller E T, Stebler B S, et al. Estrogen inhibits phorbol ester-induced Iκβα transcription and protein degradation. Biochem Biophys Res Commun 1998; 244: 691-5.
19. Hayashi H, Takikawa T, Nishimura N, et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986-8.
20. Bonkovsky H L, Banner B F, Rothman A L. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759-68.
21. Shimizu I, Omoya T, Takaoka T, et al. Serum amino-terminal propeptide of type III procollagen and 7S domain of type IV collagen correlate with hepatic iron concentration in patients with chronic hepatitis C following alpha-interferon therapy. J Gastroenterol Hepatol 2001; 16: 196-201.
22. Stohs S J, Bagchi D. Oxidative mechanisms in the toxicity of metal ions. Free Radic Biol Med 1995; 18: 321-36.
23. Berger M, de Hazen M, Nejjari A, et al. Radical oxidation reactions of the purine moiety of 2′-deoxyribonucleosides and DNA by iron-containing minerals. Carcinogenesis 1993; 14: 41-6.
24. Farinati F, Cardin R, de Maria N, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-56.
25. Pfeilschifter J, Koditz R, Pfohl M, et al. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002; 23: 90-119.
26. Rogers A, Eastell R. The effect of 17β-estradiol on production of cytokines in cultures of peripheral blood. Bone 2001; 29: 30-4.
27. Kishihara Y, Hayashi J, Yoshimura E, et al. IL-1 β and TNF-α produced by peripheral blood mononuclear cells before and during interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1996; 41: 315-21.
28. Kilbourne E J, Scicchitano M S. The activation of plasminogen activator inhibitor-1 expression by IL-1 β is attenuated by estrogen in hepatoblastoma HepG2 cells expressing estrogen receptor alpha. Thromb Haemost 1999; 81: 423-7.
29. Ozveri E S, Bozkurt A, Haklar G, et al. Estrogens ameliorate remote organ inflammation induced by burn injury in rats. Inflamm Res 2001; 50: 585-91.
30. Khan M H, Farrell G C, Byth K, et al. Which patients with hepatitis C develop liver complications? Hepatology 2000; 31: 513-20.
31. Bruno S, Silini E, Crosignani A, et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25: 754-8.
32. Hagiwara H, Hayashi N, Mita E, et al. Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1993; 17: 545-50.
33. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Dis Study Group Hepatol 1998; 27: 1394-402.
34. Villa E, Camellini L, Dugani A, et al. Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma. Cancer Res 1995; 55: 498-500.
35. Villa E, Dugani A, Moles A, et al. Variant liver estrogen receptor transcripts already occur at an early stage of chronic liver disease. Hepatology 1998; 27: 983-8.
36. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993; 18: 47-53.
37. Tsutsumi M, Ishizaki M, Takada A. Relative risk for the development of hepatocellular carcinoma in alcoholic patients with cirrhosis: a multiple logistic-regression coefficient analysis. Alcohol Clin Exp Res 1996; 20: 758-62.
38. Shimizu I, Mizobuchi Y, Ma Y-R, et al. Suppressive effect of estradiol on chemical hepatocarcinogenesis in rats. Gut 1998; 42: 112-9.
39. Hochstein P, Atallah A S. The nature of oxidants and antioxidant systems in the inhibition of mutation and cancer. Mutat Res 1988; 202: 363-75.
40. Ames B N. Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science 1983; 221: 1256-64.
41. Jansson J O, Ekberg S, Isaksson O, et al. Imprinting of growth hormone secretion, body growth, and hepatic steroid metabolism by neonatal testosterone. Endocrinology 1985; 117: 1881-9.
42. Blanck A, Eriksson L C, Gustafsson J A, et al. Sex-differentiated and growth-hormone-regulated mitoinhibition in rat liver during treatment with 2-acetylaminofluorene and partial hepatectomy in the resistant hepatocyte model. Carcinogenesis 1991; 12: 1259-64.
43. Scheuer P J, Ashrafzadeh P, Sherlock S, et al. The pathology of hepatitis C. Hepatology 1992; 15: 567-71.
44. Bach N, Thung S N, Schaffner F. The histological features of chronic hepatitis C and autoimmune chronic hepatitis: a comparative analysis. Hepatology 1992; 15: 572-7.
45. Lefkowitch J H, Schiff E R, Davis G L, et al. Pathological diagnosis of chronic hepatitis C. A multicenter comparative study with chronic hepatitis B. The Hepatitis Interventional Ther Group Gastroenterol 1993; 104: 595-603.
46. Moriya K, Yotsuyanagi H, Shintani Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J General Virol 1997; 78: 1527-31.
47. Moriya K, Fujie H, Shintani Y, et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998; 4: 1065-7.
48. Gressner A M, Lotfi S, Gressner G, et al. Identification and partial characterization of a hepatocyte-derived factor promoting proliferation of cultured fat-storing cells (parasinusoidal lipocytes). Hepatology 1992; 16: 1250-66.
49. Letteron P, Duchatelle V, Berson A, et al. Increased ethane exhalation, an in vivo index of lipid peroxidation, in alcohol-abusers. Gut 1993; 34: 409-14.
50. Letteron P, Fromenty B, Terris B, et al. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996; 24: 200-8.
51. Berson A, De B V, Letteron P, et al. Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology 1998; 114: 764-74.
52. Adinolfi L E, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33: 1358-64.
53. Nemoto Y, Toda K, Ono M, et al. Altered expression of fatty acid-metabolizing enzymes in aromatase-deficient mice. J Clin Invest 2000; 105: 1819-25.
54. Shimizu I, Omoya T, Kondo Y, et al. Estrogen therapy in a male patient with chronic hepatitis C and irradiation-induced testicular dysfunction. Intern Med 2001; 40: 100-4.
55. Yasuda M, Shimizu I, Shiba M, et al. Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats. Hepatology 1999; 29: 719-27.
56. Shimizu I, Mizobuchi Y, Shiba M, et al. Inhibitory effect of estradiol on activation of rat hepatic stellate cells in vivo and in vitro. Gut 1999; 44: 127-36.
57. Chojkier M, Houglum K, Lee K S, et al. Long- and short-term D-α-tocopherol supplementation inhibits liver collagen alpha; 1: gene expression. Am J Physiol 1998; 275: G1480-5.
58. Boigk G, Stroedter L, Herbst H, et al. Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 1997; 26: 643-9.
59. Shimizu I, Ma Y-R, Mizobuchi Y, et al. Effects of Shosaiko-to, a Japanese herbal medicine, on hepatic fibrosis in rats. Hepatology 1999; 29: 149-60.
60. Omoya T, Shimizu I, Liu F, et al. Estradiol enhances biological defence activities against oxidative stress and prevents hepatic fibrosis. Hepatology 1999; 30: 490A.
61. Fischer-Dzoga K, Wissler R W, Vesselinovitch D. The effect of estradiol on the proliferation of rabbit aortic medial tissue culture cells induced by hyperlipemic serum. Exp Mol Pathol 1983; 39: 355-63.
62. Vargas R, Wroblewska B, Rego A, et al. Oestradiol inhibits smooth muscle cell proliferation of pig coronary artery. Br J Pharmacol 1993; 109: 612-7.
63. Lindner V, Kim S K, Karas R H, et al. Increased expression of estrogen receptor-β mRNA in male blood vessels after vascular injury. Circ Res 1998; 83: 224-9.
64. Pinzani M, Failli P, Ruocco C, et al. Fat-storing cells as liver-specific pericytes. Spatial dynamics of agonist-stimulated intracellular calcium transients. J Clin Invest 1992; 90: 642-6.
65. Iafrati M D, Karas R H, Aronovitz M, et al. Estrogen inhibits the vascular injury response in estrogen receptor α-deficient mice. Nat Med 1997; 3: 545-8.
66. Bayard F, Clamens S, Meggetto F, et al. Estrogen synthesis, estrogen metabolism, and functional estrogen receptors in rat arterial smooth muscle cells in culture. Endocrinology 1995; 136: 1523-9.
67. Kwan G, Neugarten J, Sherman M, et al. Effects of sex hormones on mesangial cell proliferation and collagen synthesis. Kidney Int 1996; 50: 1173-9.
68. Bataller R, Gines P, Nicolas J M, et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000; 118: 1149-56.
69. Rockey D C, Housset C N, Friedman S L. Activation-dependent contractility of rat hepatic lipocytes in culture and in vivo. J Clin Invest 1993; 92: 1795-804.
70. Sakamoto M, Ueno T, Kin M, et al. Ito cell contraction in response to endothelin-1 and substance P. Hepatology 1993; 18: 978-83.
71. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997; 25: 2-5.
72. Rockey D C, Chung J J. Inducible nitric oxide synthase in rat hepatic lipocytes and the effect of nitric oxide on lipocyte contractility. J Clin Invest 1995; 95: 1199-206.
73. Helyar L, Bundschuh D S, Laskin J D, et al. Induction of hepatic Ito cell nitric oxide production after acute endotoxemia. Hepatology 1994; 20: 1509-15.
74. Shah V, Haddad F G, Garcia-Cardena G, et al. Liver sinusoidal endothelial cells are responsible for nitric oxide modulation of resistance in the hepatic sinusoids. J Clin Invest 1997; 100: 2923-30.
75. Ikejima K, Enomoto N, Iimuro Y, et al. Estrogen increases sensitivity of hepatic Kupffer cells to endotoxin. Am J Physiol 1998; 274: G669-76.
76. Sakamoto M, Uen T, Nakamura T, et al. Estrogen upregulates nitric oxide synthase expression in cultured rat hepatic sinusoidal endothelial cells. J Hepatol 2001; 34: 858-64.
77. Williams M R, Ling S, Dawood T, et al. Dehydroepiandrosterone inhibits human vascular smooth muscle cell proliferation independent of ARs and ERs. J Clin Endocrinol Metab 2002; 87: 176-81.
78. Ashcroft G S, Dodsworth J, van Boxtel E, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-β1 levels. Nat Med 1997; 3: 1209-15.
79. Bissell D M. Sex and hepatic fibrosis. Hepatology 1999; 29: 988-9.
80. Pinzani M, Romanelli R G, Magli S. Progression of fibrosis in chronic liver diseases: time to tally the score. J Hepatol 2001; 34: 764-7.
81. Grady D, Rubin S M, Petitti D B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37.
82. Colditz G A, Hankinson S E, Hunter D J, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332: 1589-93.
83. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy. collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997; 351: 1047-59.
84. Alvaro D, Alpini G, Onori P, et al. Estrogens stimulate proliferation of intrahepatic biliary epithelium in rats. Gastroenterology 2000; 119: 1681-91.